Hormonal
GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control primarily through delayed gastric emptying, reduced appetite, and central nervous system-mediated satiety pathways.
GLP-1 and dual agonists are highly effective for weight loss and blood sugar control, working by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize stomach upset, and increase gradually as tolerated. Expect significant weight loss (up to 20% in some trials) and improved glucose levels, but be prepared for potential gastrointestinal side effects like nausea.
GLP-1 RAs delay gastric emptying and reduce stomach motility in obese patients, contributing to their satiating effect... intracerebroventricular administration of GLP-1 decreased food intake in rats, suggesting GLP-1 RAs are involved in a central nervous system pathway... The combined activation of GLP-1 and GIP receptors more effectively reduces glucose levels and stimulates weight loss compared to the placebo, semaglutide and dulaglutide, or insulin.
Why this rating
Based on a comprehensive review of multiple large-scale clinical trials (e.g., STEP, SURPASS) and FDA approvals.
Source
A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
Jee Sun Min et al. · Drug Design Development and Therapy · 2025
DOI 10.2147/dddt.s506957
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →